You are a famous and esteemed scientist and professor in health economics with a proven track record of publications in top academic journals such as Journal of Health Economics, Health Economics, Social Science & Medicine, Annals of Internal Medicine, Lancet, JAMA, and BMJ. Your writing has a scientific rigor that ensures clarity and precision in language. I will give you points that cover the main content of each section (i.e., introduction, methods, results, and discussion), and you will use the points to write a paper that will be submitted to JAMA Network Open. Please use the writing style that fits the target journal. The language should be grammatically correct, and that the ideas are presented in a clear and concise manner. Please ensure the writing to meet the academic style, improve the spelling, grammar, clarity, concision and overall readability. Please use appropriate and precise words and sentences should flow fluently. Now, I will feed you the points of my abstract , and please use them to generate the abstract section. Abstract
Importance: Familial hypercholesterolemia is a prevalent genetic disorder globally, significantly impacting severe cardiovascular diseases. As genetic disease screening and treatment advance, evaluating the economic implications of familial hypercholesterolemia becomes increasingly crucial. International disparities persist, emphasizing the need for a comprehensive economic analysis of familial hypercholesterolemia screening for valuable insights.

Objective: To conduct a global analysis of economic assessments pertaining to familial hypercholesterolemia, synthesize evidence, and offer economic insights into the impact of familial hypercholesterolemia screening on population equity.

Data Sources: A systematic search was conducted on familial hypercholesterolemia screening economic evaluation literature from 2000 to October 2023, utilizing PubMed, Web of Science, and Embase. Inclusion and quality assessments employed the QHES and CHEERS 2022 instruments.

Study Selection: Out of 189 identified articles, 19 familial hypercholesterolemia screening economic evaluation studies were included.

Methods: A systematic literature analysis evaluated 19 familial hypercholesterolemia screening economic evaluation studies. Through meta-analysis, evidence was synthesized, comprehensively analyzing the total cost-effectiveness and total net health benefits of cascade and universal screening for familial hypercholesterolemia across various health outcomes. Aggregate distributional cost-effectiveness analysis assessed FH screening's impact on population equity.

Results: Economic evaluations of familial hypercholesterolemia screening exhibited significant variations across countries. Cost-effectiveness analysis indicated that familial hypercholesterolemia screening is cost-effective in the majority of countries. Meta-analysis synthesized the economic impacts of seven sets of cascade and universal screening across diverse health outcomes. Aggregate distributional cost-effectiveness analysis suggested the potential for familial hypercholesterolemia screening strategies to alleviate health inequalities.

Conclusions and Relevance: This study offers a global perspective on the economic evaluation of familial hypercholesterolemia screening. Despite international differences, the majority of cases suggest that familial hypercholesterolemia screening is cost-effective, contributing to improved health equity and overall population health. The optimistic outlook underscores the significance of familial hypercholesterolemia screening in shaping future health decisions.